GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » Price-to-Funds-From-Operations

Delcath Systems (STU:DV3R) Price-to-Funds-From-Operations : (As of Apr. 28, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Delcath Systems Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Delcath Systems Business Description

Traded in Other Exchanges
Address
566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.